• Narrative Review
  • Treatment: Pharmacological
Clinical RelevanceDOI 5 min read
Jump to:

Full research — for clinicians and curious readers

Study Summary

Background

Musculoskeletal pain and biomechanical dysfunction are common problems that can limit rehabilitation and recovery from injury. While traditional treatments include physical therapy, medications, and injections, there has been growing interest in using botulinum neurotoxin (BoNT) for painful musculoskeletal conditions. BoNT works by blocking nerve signals to muscles and also appears to affect pain pathways in sensory nerves. However, high-quality evidence for many of these off-label uses remains limited.

This review examines the current literature on BoNT use for several specific musculoskeletal conditions.

What They Did

The authors conducted a narrative review of published literature on the use of botulinum toxin for five musculoskeletal conditions: chronic exertional compartment syndrome (CECS), plantar fasciopathy, osteoarthritis, lateral epicondylosis, and myofascial pain syndrome (MPS). They searched for and analyzed available studies including randomized controlled trials, case series, systematic reviews, and meta-analyses. For each condition, they described the proposed mechanism of BoNT action, summarized the existing evidence, and described their own clinical practice patterns for patient selection and injection techniques.

What They Found

For CECS, a 2013 case series of 16 patients showed normalized intramuscular pressure in 87.5% (14/16) and eliminated exertional pain in 94% (15/16) of patients, with 11 patients experiencing transient dorsiflexion weakness. An unpublished retrospective review at their institution found 66% (19/29) of patients returned to desired activity levels. For plantar fasciopathy, a 2013 randomized trial of 40 patients found BoNT-A superior to dexamethasone at 2-6 months, and a 2016 meta-analysis of 22 RCTs found BoNT-A relieved pain in the first 6 months with no significant side effects. For knee osteoarthritis, a 2016 RCT of 44 patients showed VAS scores reduced from 5.05 ± 1.12 to 2.89 ± 1.04 at 1 week (P < 0.001).

For lateral epicondylosis, a 2018 RCT of 60 patients found 51.7% (15/29) of the BoNT-A group had greater than 50% decrease in pain compared with 25% (7/28) of placebo patients at 3 months. For MPS, a 2014 Cochrane review of 4 studies with 244 patients found inconclusive evidence for BoNT-A. A 2018 systematic review and meta-analysis of 33 studies found local anesthetic injections more effective than BoNT-A at reducing pain, with BoNT-A results described as inconsistent.

What This Means

BoNT-A shows promise as an off-label treatment for several musculoskeletal conditions, particularly when conservative treatments have failed. The strongest emerging evidence appears to be for plantar fasciopathy and lateral epicondylosis, with moderate support for CECS and osteoarthritis. However, for myofascial pain syndrome specifically, the evidence does not support BoNT-A as superior to other injection therapies like local anesthetics. Clinicians should counsel patients about off-label use, set clear functional goals, and continue conservative management alongside BoNT treatment.

The authors emphasize that larger, higher-quality studies with longer follow-up periods are needed to establish definitive recommendations for dosing, injection sites, and long-term safety across all these conditions.

35/100
Evidence StrengthLimited
Study Quality
Sample Size
Replication
Normalized intramuscular pressure in CECS patients
87.5%
Exertional pain eliminated in CECS patients
94%
BoNT-A patients with >50% pain reduction in lateral epicondylosis
51.7%
Statistical significance for knee OA VAS reduction at 1 week
P < 0.001

Results Comparison

Pain reduction in lateral epicondylosis (>50% decrease at 3 months)

%
BoNT-A51.7 %
Placebo25 %

Key Findings

FindingDetailImpact
BoNT-A shows promise for chronic exertional compartment syndromeA 2013 case series of 16 patients demonstrated normalized intramuscular pressure in 87.5% (14/16) and eliminated exertional pain in 94% (15/16), with an unpublished institutional review showing 66% (19/29) returned to desired activity levels.Medium
BoNT-A effective for plantar fasciopathy failing conservative careA 2013 randomized trial of 40 patients showed significant improvement in pain and function scores between 2 and 6 months compared with dexamethasone, and a 2016 meta-analysis of 22 RCTs found BoNT-A relieved pain in the first 6 months with no significant side effects.Medium
BoNT-A provides short-term pain relief for knee osteoarthritisA 2016 RCT of 44 patients showed VAS scores reduced from 5.05 ± 1.12 pretreatment to 2.89 ± 1.04 at 1 week (P < 0.001) and 3.45 ± 1.70 at 6 months compared with an education-only control group.Medium
BoNT-A effective for refractory lateral epicondylosisA 2018 RCT of 60 patients found 51.7% (15/29) of the BoNT-A group had greater than 50% decrease in pain compared with 25% (7/28) of placebo patients at 3 months, with significant reduction in VAS for pain and quality of life.Medium
Inconclusive evidence for BoNT-A in myofascial pain syndromeA 2014 Cochrane review of 4 studies with 244 patients found inconclusive evidence, and a 2018 systematic review and meta-analysis of 33 studies found local anesthetic injections more effective than BoNT-A at reducing pain, with BoNT-A results described as inconsistent.High
Study Methodology
Study Design
Narrative review of published literature
Sample Size
N/A
Duration
Varies by cited study
Population
Patients with various musculoskeletal conditions
Outcome Measures
VAS pain scores · pressure pain threshold · functional outcome scales · intramuscular pressure

Strengths

  • Comprehensive coverage of multiple musculoskeletal conditions
  • Includes authors' clinical experience and practical protocols
  • Critically evaluates quality of available evidence
  • Discusses safety considerations and adverse effects

Limitations

  • Narrative review without systematic search methodology
  • Relies heavily on small studies and case series for some conditions
  • Authors' institutional data unpublished and not peer-reviewed
  • Multiple conditions reviewed limits depth for any single diagnosis

Key Takeaways for Patients

What This Means for You

  1. Botox injections are being studied for several types of muscle and joint pain, but many uses are considered off-label

  2. For myofascial pain syndrome with trigger points, current evidence does not show Botox works better than other injection treatments like local anesthetics

  3. For plantar fasciitis and tennis elbow, research suggests Botox may help when other treatments have failed

  4. Always discuss the risks, benefits, and limitations of Botox with your doctor, as effects are temporary and repeat injections may be needed

Read the Full Paper

Access the complete peer-reviewed study from Current Sports Medicine Reports

View Full Study

Related Research

●●●●● LandmarkNarrative Review

Pharmacologic treatment of fibromyalgia: an update

Yang Li et al.·Frontiers in Pharmacology·2025

A 2025 narrative review concluding that current fibromyalgia drugs help only a minority of patients and should be used as part of an individualized, multimodal plan alongside exercise, education, and psychological support.

PharmacologicalRead →
●●●●● LandmarkNarrative Review

Pharmacological Treatment of Fibromyalgia Syndrome: A Practice-Based Review

Valeria Giorgi et al.·Current Pain and Headache Reports·2024

A practice-based narrative review of the drugs used to treat fibromyalgia, concluding that current pharmacological options offer limited benefit and are best applied within a personalized, multidisciplinary approach.

PharmacologicalRead →
●●●●● LandmarkNarrative Review

Review of pharmacological therapies in fibromyalgia syndrome

Winfried Häuser et al.·Arthritis Research & Therapy·2014

A guideline- and meta-analysis-based review concluding that fibromyalgia drugs (amitriptyline, pregabalin, duloxetine, milnacipran) offer only modest, often short-lived benefit, so medication should supplement—not replace—non-drug self-management.

PharmacologicalRead →
●●●●● LandmarkNarrative Review

Myofascial Pain Disorders: Theory to Therapy

Wheeler, Anthony H.·Drugs·2004

Comprehensive review of myofascial pain treatment emphasizing multimodal approach combining pharmacotherapy with injection therapy. Botulinum toxin emerges as promising treatment when combined with physical therapy.

PharmacologicalRead →